Skip to main content
Top
Published in: AIDS and Behavior 11/2016

01-11-2016 | Original Paper

Sharing of Investigational Drug Among Participants in the Voice Trial

Authors: Jeeva Moodley, Sarita Naidoo, Jayajothi Moodley, Gita Ramjee

Published in: AIDS and Behavior | Issue 11/2016

Login to get access

Abstract

Product sharing among participants can impact on adherence and compromise the outcome in clinical trials. We describe incidents of product sharing at the Durban clinical research sites conducting the VOICE trial. The Durban sites enrolled 2750 women with 1103 and 1647 participants randomized to the vaginal gel and oral tablet arms respectively. Monthly pill and applicator counts including product assessments were conducted by pharmacists. Discrepancies with product counts prompted discussions with participants. Thirty-two cases of product sharing were identified. Vaginal gels were more commonly shared than oral tablets. Product sharing between study participants and their female friends or relatives living in the same household was identified as the most common source of product sharing in this analysis. Study product counts and pharmacist-driven discussions with participants may help to identify reasons for product sharing and inform the development of strategies for PrEP implementation outside of the research setting.
ClinicalTrials.gov number: NCT00705679
Literature
1.
go back to reference Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef Karim QA, Karim SSA, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRef
2.
go back to reference Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
3.
go back to reference Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV pathogenesis, treatment and prevention; Rome: 2011. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. 6th IAS Conference on HIV pathogenesis, treatment and prevention; Rome: 2011.
4.
go back to reference Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
6.
go back to reference Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
7.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
8.
go back to reference Rees H, Delany-Moretlwe S, Baron D, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on retroviruses and opportunistic infections (CROI); Seattle: 2015. Rees H, Delany-Moretlwe S, Baron D, et al. FACTS 001 phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. Conference on retroviruses and opportunistic infections (CROI); Seattle: 2015.
9.
go back to reference Molina JM, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on retroviruses and opportunistic infections; Seattle: 2015. Molina JM, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on retroviruses and opportunistic infections; Seattle: 2015.
10.
go back to reference McCormack S, Dunn D. Pragmatic open-label randomised trial of Preexposure prophylaxis: The PROUD study. Conference on retroviruses and opportunistic infections (CROI); Seattle: 2015. McCormack S, Dunn D. Pragmatic open-label randomised trial of Preexposure prophylaxis: The PROUD study. Conference on retroviruses and opportunistic infections (CROI); Seattle: 2015.
11.
go back to reference Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100:S3–8.CrossRefPubMed Devlin B, Nuttall J, Wilder S, Woodsong C, Rosenberg Z. Development of dapivirine vaginal ring for HIV prevention. Antiviral Res. 2013;100:S3–8.CrossRefPubMed
12.
go back to reference Spreen B, Rinehart A, Smith K, Margolis D, Ford S, Piscitelli S. HIV PrEP dose rationale for cabotegravir (GSK1265744) long-acting injectable nanosuspension. AIDS Res Human Retrovir. 2014;30(S1):A12.CrossRef Spreen B, Rinehart A, Smith K, Margolis D, Ford S, Piscitelli S. HIV PrEP dose rationale for cabotegravir (GSK1265744) long-acting injectable nanosuspension. AIDS Res Human Retrovir. 2014;30(S1):A12.CrossRef
13.
go back to reference Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015;10(4):253–7.CrossRefPubMed Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015;10(4):253–7.CrossRefPubMed
15.
go back to reference Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking. Fam Med. 2007;39(2):132.PubMed Viera AJ, Bangdiwala SI. Eliminating bias in randomized controlled trials: importance of allocation concealment and masking. Fam Med. 2007;39(2):132.PubMed
16.
go back to reference Ambia J, Agot K. Barriers and facilitators of adherence in user-dependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013;1:12–29.CrossRef Ambia J, Agot K. Barriers and facilitators of adherence in user-dependent HIV prevention trials, a systematic review. Int STD Res Rev. 2013;1:12–29.CrossRef
17.
go back to reference Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;1(44):S91–8.CrossRef Koenig LJ, Lyles C, Smith DK. Adherence to antiretroviral medications for HIV pre-exposure prophylaxis. Am J Prev Med. 2013;1(44):S91–8.CrossRef
18.
go back to reference Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquired Immune Deficiency Syndromes. 2010;55(1):8.CrossRef Underhill K, Operario D, Skeer M, Mimiaga M, Mayer K. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice. J Acquired Immune Deficiency Syndromes. 2010;55(1):8.CrossRef
19.
go back to reference Woodsong C, MacQueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013; 16(1). Woodsong C, MacQueen K, Amico KR, et al. Microbicide clinical trial adherence: insights for introduction. J Int AIDS Soc. 2013; 16(1).
20.
go back to reference Jacob ST, Baeten JM, Hughes JP, et al. A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav. 2011;15(5):897–904.CrossRefPubMedPubMedCentral Jacob ST, Baeten JM, Hughes JP, et al. A post-trial assessment of factors influencing study drug adherence in a randomized biomedical HIV-1 prevention trial. AIDS Behav. 2011;15(5):897–904.CrossRefPubMedPubMedCentral
21.
go back to reference van de Wijgert J, Jones H, Pistorius A, et al. Phase III microbicide trial methodology: opinions of experienced expanded safety trial participants in South Africa. SAHARA J. 2006;2(3):311–9.CrossRef van de Wijgert J, Jones H, Pistorius A, et al. Phase III microbicide trial methodology: opinions of experienced expanded safety trial participants in South Africa. SAHARA J. 2006;2(3):311–9.CrossRef
22.
go back to reference Mâsse BR, Boily M-C, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg themes Epidemiol. 2009;6(1):5.CrossRefPubMedPubMedCentral Mâsse BR, Boily M-C, Dimitrov D, Desai K. Efficacy dilution in randomized placebo-controlled vaginal microbicide trials. Emerg themes Epidemiol. 2009;6(1):5.CrossRefPubMedPubMedCentral
23.
go back to reference Lader EW, Cannon CP, Ohman EM, et al. The clinician as investigator participating in clinical trials in the practice setting. Circulation. 2004;109(21):2672–9.CrossRefPubMed Lader EW, Cannon CP, Ohman EM, et al. The clinician as investigator participating in clinical trials in the practice setting. Circulation. 2004;109(21):2672–9.CrossRefPubMed
24.
go back to reference Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health. 2008;98(6):1115.CrossRefPubMedPubMedCentral Goldsworthy RC, Schwartz NC, Mayhorn CB. Beyond abuse and exposure: framing the impact of prescription-medication sharing. Am J Public Health. 2008;98(6):1115.CrossRefPubMedPubMedCentral
25.
go back to reference Daniel KL, Honein MA, Moore CA. Sharing prescription medication among teenage girls: potential danger to unplanned/undiagnosed pregnancies. Pediatrics. 2003;111(Supplement 1):1167–70.PubMed Daniel KL, Honein MA, Moore CA. Sharing prescription medication among teenage girls: potential danger to unplanned/undiagnosed pregnancies. Pediatrics. 2003;111(Supplement 1):1167–70.PubMed
26.
go back to reference Ellis J, Mullan J. Prescription medication borrowing and sharing: risk factors and management. Aust Fam Physician. 2009;38(10):816.PubMed Ellis J, Mullan J. Prescription medication borrowing and sharing: risk factors and management. Aust Fam Physician. 2009;38(10):816.PubMed
27.
28.
go back to reference Pool R, Montgomery CM, Morar NS, et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS ONE. 2010;5(7):e11632.CrossRefPubMedPubMedCentral Pool R, Montgomery CM, Morar NS, et al. Assessing the accuracy of adherence and sexual behaviour data in the MDP301 vaginal microbicides trial using a mixed methods and triangulation model. PLoS ONE. 2010;5(7):e11632.CrossRefPubMedPubMedCentral
29.
go back to reference Corneli AL, McKenna K, Perry B, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J AIDS. 2015;68(5):578–84. Corneli AL, McKenna K, Perry B, et al. The science of being a study participant: FEM-PrEP participants’ explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. J AIDS. 2015;68(5):578–84.
30.
go back to reference Dimitrov D, Boily M-C, Mâsse BR, Brown ER. Impact of pill sharing on drug resistance due to a wide-scale oral prep intervention in generalized epidemics. J AIDS Clin Res. 2012; (4). Dimitrov D, Boily M-C, Mâsse BR, Brown ER. Impact of pill sharing on drug resistance due to a wide-scale oral prep intervention in generalized epidemics. J AIDS Clin Res. 2012; (4).
31.
go back to reference van der Straten A, Mayo A, Brown ER, et al. Perceptions and experiences with the VOICE adherence strengthening program (VASP) in the MTN-003 trial. AIDS Behav. 2014;19(5):770–83.CrossRef van der Straten A, Mayo A, Brown ER, et al. Perceptions and experiences with the VOICE adherence strengthening program (VASP) in the MTN-003 trial. AIDS Behav. 2014;19(5):770–83.CrossRef
32.
go back to reference van der Straten A, Musara P, Etima J, et al. Disclosure of pharmacokinetic (PK) drug results promotes open discourse on non-adherence among women in VOICE. AIDS Res Hum Retrovir. 2014;30(S1):A42–3.CrossRef van der Straten A, Musara P, Etima J, et al. Disclosure of pharmacokinetic (PK) drug results promotes open discourse on non-adherence among women in VOICE. AIDS Res Hum Retrovir. 2014;30(S1):A42–3.CrossRef
33.
go back to reference El-Khatib Z, Richter M. (ARV-) free state? the moratorium’s threat to patients’ adherence and the development of drug-resistant HIV. SAMJ. 2009;99(6):412–4.PubMed El-Khatib Z, Richter M. (ARV-) free state? the moratorium’s threat to patients’ adherence and the development of drug-resistant HIV. SAMJ. 2009;99(6):412–4.PubMed
34.
go back to reference Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and street markets for ARVs: potential implications for PrEP rollout in the USA. AIDS care. 2014;26(4):411–5.CrossRefPubMed Kurtz SP, Buttram ME, Surratt HL. Vulnerable infected populations and street markets for ARVs: potential implications for PrEP rollout in the USA. AIDS care. 2014;26(4):411–5.CrossRefPubMed
35.
go back to reference Rosenthal E, Piroth L, Cua E, et al. Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study). AIDS Care. 2014;26(2):176–85.CrossRefPubMed Rosenthal E, Piroth L, Cua E, et al. Preexposure prophylaxis (PrEP) of HIV infection in France: a nationwide cross-sectional study (PREVIC study). AIDS Care. 2014;26(2):176–85.CrossRefPubMed
36.
go back to reference van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRefPubMedPubMedCentral van der Straten A, Stadler J, Montgomery E, et al. Women’s experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014;9(2):e89118.CrossRefPubMedPubMedCentral
Metadata
Title
Sharing of Investigational Drug Among Participants in the Voice Trial
Authors
Jeeva Moodley
Sarita Naidoo
Jayajothi Moodley
Gita Ramjee
Publication date
01-11-2016
Publisher
Springer US
Published in
AIDS and Behavior / Issue 11/2016
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1414-x

Other articles of this Issue 11/2016

AIDS and Behavior 11/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.